HC Wainwright Has Bullish Forecast for REGENXBIO Q1 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a note issued to investors on Monday, March 17th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings of ($1.21) per share for the quarter, up from their previous forecast of ($1.35). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million.

A number of other analysts have also commented on RGNX. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. Chardan Capital reissued a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Thursday. Finally, Morgan Stanley boosted their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, March 14th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.88.

REGENXBIO Stock Performance

RGNX opened at $8.36 on Wednesday. The company has a fifty day moving average price of $7.29 and a two-hundred day moving average price of $8.93. REGENXBIO has a 52 week low of $5.62 and a 52 week high of $23.14. The firm has a market capitalization of $414.20 million, a PE ratio of -1.66 and a beta of 1.35.

Hedge Funds Weigh In On REGENXBIO

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in REGENXBIO by 9.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 1,982 shares during the period. Teacher Retirement System of Texas boosted its stake in REGENXBIO by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 2,088 shares during the period. DnB Asset Management AS boosted its stake in REGENXBIO by 20.1% in the 4th quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 2,434 shares during the period. Finally, GAMMA Investing LLC boosted its stake in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares during the period. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.